TNF and cancer: In light of the enormous interest attracted by immune checkpoint inhibitors (ICI) in the treatment of cancer and the frequent occurrence of immune-related adverse events (irAEs) associated with their use, it has also been debated whether the use of biological TNF inhibitors may impact the pharmacological response to ICI and the development of irAEs.